- Shares of Durata Therapeutics (DRTX +18.8%) pop on a 4x surge in volume as the market comes around to the potential upside of its dalbavancin license deal with Angelini. The Italian firm will commercialize the antibiotic in 36 countries. Durata will receive a $15M upfront payment and another $10M upon EMA approval plus milestones.